The final analysis of the phase 2 ASPEN-06 is underway and expected to complete in 2024. Evorpacept (ALX148), a ...

Marcia S. Brose, MD, PhD, FASCO, discusses the landscape of thyroid cancer by explaining the complexities and promising ...

Based on the recommendation of an independent data monitoring committee and positive topline data, accrual in the KMT2A-rearranged cohorts of the AUGMENT-101 trial of revumenib will be stopped.

In an interview, Nathan Bahary, MD, PhD, explains what factors have contributed to the rise in oncology drug shortages, and emphasizes the importance of proactive measures moving forward, while also ...

Phase 2 studies are investigating BDC-1001 in HER2-positive gastroesophageal, colorectal, breast, and endometrial cancers.

The FDA and Takeda have decided to voluntarily withdraw mobocertinib, a drug for patients with EGFR exon20 insertion mutation-positive non–small cell lung cancer.

Liquid biopsy is offering a noninvasive, real-time, and personalized approach to tumor assessment, and is already revolutionizing the field of clinical oncology.

The fast track designation for AVB-001 granted by the FDA recognizes its potential as a treatment option for patients with relapsed/refractory ovarian cancer.

Zev A. Wainberg, MD, discusses the pressing relevance of the outcomes of the NAPOLI 3 trial, which were presented at the 2023 Gastrointestinal Cancers Symposium.

Justin Taylor, MD, discusses the treatment landscape for chronic lymphocytic leukemia and background on his early research assessing NX-2127 for this patient population.

Results from the phase 3 NETTER-2 study will be presented at an upcoming medical conference and shared with drug regulators.

Researchers presented updated results from longer-term follow-up studies of GC012F for newly-diagnosed multiple myeloma ...